HER2/Neu Positive Completed Phase 3 Trials for Epirubicin (DB00445)

IndicationStatusPhase
DBCOND0037939 (HER2/Neu Positive)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00513292Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by SurgeryTreatment